BrightGene Bio-Medical Technology Co., Ltd.

BrightGene Bio-Medical Technology Co., Ltd. is a Chinese innovative pharmaceutical company. According to its official website, it was established in 2001 and listed on the STAR Market in 2019 under stock code 688166. It describes itself as an international innovative pharmaceutical enterprise that develops, manufactures and sells high-quality intermediates, specialty APIs and complex formulations, with marketed and pipeline products covering metabolic, oncology, respiratory, immunosuppression and antiviral/antifungal therapeutic areas. Its product and service lines include formulations, APIs and intermediates, and veterinary drugs.

BrightGene Bio-Medical Technology Co., Ltd. was established in 2001 and listed on the STAR Market in 2019 under stock code 688166, according to its official website. The company states that it has built multiple high-barrier technology platforms through self-research and has become a globally leading pharmaceutical enterprise in the development, production and sales of high-quality intermediates, specialty APIs and complex formulations. Its marketed and pipeline products cover metabolic, oncology, respiratory, immunosuppression and antiviral/antifungal therapeutic areas. As of the disclosure date of its Q1 2025 report, BGM0504 injection (a GLP-1 and GIP dual receptor agonist) was in Phase III clinical trials in China for both weight loss and type 2 diabetes indications; the weight-loss indication had received IND approval in the United States, where a US bridging clinical study was essentially completed and a clinical summary report was being prepared; oral BGM0504 tablets and the innovative drug BGM1812 (a long-acting amylin analog) were in preclinical research. The company has also established five technology platforms based on drug-device combination product development: blow-fill-seal integrated, oral soft mist inhalation, inhaled dry powder, ophthalmic nebulization delivery, and nose-to-brain delivery.

• 2025

  As of the disclosure date of the 2025 Q1 report, the BGM0504 injection (a GLP-1 and GIP dual receptor agonist) was in Phase III clinical trials in China for both weight loss and type 2 diabetes indications; its weight loss indication had received IND approval in the United States, and the US bridging clinical study was essentially complete with a clinical summary report in progress.

• 2019

  BrightGene was listed on the STAR Market of the Shanghai Stock Exchange (stock code: 688166).

• 2001

  BrightGene Bio-Medical Technology Co., Ltd. was established.

International innovative pharmaceutical enterprise developing high-barrier intermediates, specialty APIs and complex formulations.

• Entecavir Tablets (甘御®)

• Fondaparinux Sodium Injection (博舒通®)

• Eribulin Mesylate Injection (博立宁®)

• Voriconazole for Injection (博君康®)

• Dienogest Tablets (博律®)

• Carboprost Tromethamine Injection (卡保®)

• 2020

  Source

• 2020

  Contractor sues Beryon subsidiary over unpaid construction fees

  Nantong Tongbo Equipment Installation Engineering Co. sued Beryon’s wholly owned subsidiary, Beryon Biopharmaceutical Taixing, over a construction contract. Tongbo requested payment of approximately RMB 22.59 million in unpaid construction fees and approximately RMB 1.04 million in liquidated damages. Beryon said the case had not yet been heard as of its announcement.

  Source

Read more

• Unconfirmed

  Contractor sues Beryon subsidiary over unpaid construction fees[8]Contractor sues Beryon subsidiary over unpaid construction feessc.stock.cnfol.com

  Nantong Tongbo Equipment Installation Engineering Co. sued Beryon’s wholly owned subsidiary, Beryon Biopharmaceutical Taixing, over a construction contract. Tongbo requested payment of approximately RMB 22.59 million in unpaid construction fees and approximately RMB 1.04 million in liquidated damages. Beryon said the case had not yet been heard as of its announcement.

• 2020-01-14

  Contractor sues Bairui Pharmaceutical subsidiary over unpaid construction fees[9]施工承包商就未付工程款起诉博瑞医药旗下子公司finance.sina.com.cn

  Reported: 2020-01-17

  Construction contractor Nantong Tongbo Equipment Installation Engineering sued Bairui Pharmaceutical’s wholly owned subsidiary, Bairui Taixing, over a construction contract dispute, seeking about RMB 22.59 million in unpaid construction fees and about RMB 1.04 million in liquidated damages. The case had not yet been heard as of the report.

1. 1博瑞生物医药（苏州）股份有限公司bright-gene.com
2. 2博瑞生物医药（苏州）股份有限公司bright-gene.com
3. 3博瑞生物医药（苏州）股份有限公司bright-gene.com
4. 4BrightGene Bio-Medical Technology Co.wikidata.org
5. 5董事长误导性宣传在研减重药等，三次被证监局警示csrc.gov.cn
6. 6董事长误导性宣传在研减重药等，三次被证监局警示paper.cnstock.com
7. 7董事长误导性宣传在研减重药等，三次被证监局警示csrc.gov.cn
8. 8Contractor sues Beryon subsidiary over unpaid construction feessc.stock.cnfol.com
9. 9施工承包商就未付工程款起诉博瑞医药旗下子公司finance.sina.com.cn